Ozempic may be changing the brain in ways scientists are only beginning to understand

Weight-loss drugs such as Ozempic and Wegovy have transformed the treatment of obesity, but scientists are increasingly discovering that their effects may extend much further than simply making people feel less hungry.

Early research suggests GLP-1 drugs may alter activity and connections within parts of the brain involved in appetite, attention, reward and motivation, raising intriguing questions about why some people taking the medicines report changes not only in their relationship with food but also with alcohol, shopping and other previously rewarding behaviours.

Researchers are now investigating whether these drugs could influence addiction, mood, cognition and neurological disease. At the same time, scientists are urging caution about describing the effects as beneficial or harmful before considerably more research has been completed.

Semaglutide, the active ingredient in Ozempic and Wegovy, mimics the action of the naturally occurring hormone GLP-1. The medicines slow digestion, help regulate blood glucose and influence signalling involved in appetite, enabling many people with obesity to achieve substantial and sustained weight loss.

The brain, however, has always been part of that process.

GLP-1 receptors and associated pathways are found in areas involved in regulating hunger and energy balance, while researchers are increasingly interested in connections with neural systems involved in reward, motivation and behaviour.

That could help explain the phenomenon commonly described by patients as a reduction in “food noise” – persistent thoughts about food and eating which some people say become substantially quieter after starting treatment.

One small study has offered a particularly intriguing glimpse of what might be happening.

Researchers examining brain scans from 13 teenagers and young women receiving GLP-1 treatment discovered changes in connectivity within the brain’s salience network over a period of months.

The salience network helps the brain determine which internal and external information deserves attention. Rather than processing everything around us equally, it helps identify what is important and directs attention accordingly.

Researchers observed increased connections within that network following treatment, alongside changes involving reward circuitry.

Importantly, scientists do not yet know whether those changes should be considered positive, negative or simply part of the way GLP-1 medicines exert their effects.

Assistant professor Allison Shapiro of the University of Colorado Anschutz, who was involved in the research, has cautioned that the findings were unexpected and their meaning is not yet understood.

What makes the research particularly interesting is how closely it fits with experiences some patients have described.

For people who previously found themselves repeatedly thinking about food, the reduction in appetite produced by GLP-1 treatment can feel less like consciously resisting something they want and more like simply wanting it less.

Researchers are investigating whether a similar mechanism could affect other forms of reward.

Interest in GLP-1 drugs as potential treatments for addiction began long before semaglutide became widely associated with weight loss. Animal studies suggested drugs targeting the GLP-1 system could reduce alcohol consumption, prompting researchers to investigate whether similar effects might occur in humans.

Scientists are now studying GLP-1 medicines in relation to alcohol and substance use disorders, examining whether they can reduce cravings and change the way people respond to cues associated with addictive behaviour.

That research remains developing, and GLP-1 drugs are not currently approved as treatments for addiction. Nevertheless, reports from some patients of unexpectedly losing interest in alcohol after beginning treatment have added to scientific interest in the relationship between GLP-1 signalling and reward.

Other patients have described changes involving shopping, gambling or compulsive behaviours, although anecdotal experiences cannot establish that the medication caused those changes.

There is another side to the conversation.

Some people taking GLP-1 medicines have reported feeling less interested in activities they previously enjoyed, reduced sexual desire, diminished motivation or a broader sense of emotional flattening.

Researchers do not yet know whether those experiences are caused by GLP-1 treatment, how frequently they occur or whether changes in weight, diet, physical health or other factors could be responsible.

The possibility nevertheless raises an important scientific question. If a medicine can influence neural systems involved in reward sufficiently to reduce cravings for food or alcohol, could it also affect the way some people experience other rewarding parts of life?

At present, there is not enough evidence to answer that question.

Separate research is beginning to provide further clues about how semaglutide might affect the physical structure and function of the brain.

A small 2026 study followed 26 adults with overweight or obesity who received semaglutide for 24 weeks and underwent brain imaging before and after treatment.

Researchers identified changes in the left temporal lobe, including an increase in grey matter volume in one region alongside changes in measures of brain activity in others.

Intriguingly, the neurological changes were not statistically associated with the amount of weight participants lost or improvements in their metabolic health.

The researchers described the findings as evidence of neurobiological remodelling and suggested semaglutide could potentially have neuroprotective effects.

However, the study was small, had no untreated control group and did not find a significant improvement in participants’ performance on cognitive tests. It therefore cannot establish that semaglutide improves brain health or cognition.

Understanding whether GLP-1 drugs could protect the brain has become another major area of research.

Scientists have investigated the medicines in Alzheimer’s and Parkinson’s disease because of potential effects involving inflammation, metabolism and the survival and functioning of brain cells.

One of the biggest tests of that idea produced disappointing results. Large phase three trials examining oral semaglutide in people with early Alzheimer’s disease failed to demonstrate a significant slowing of cognitive and functional decline.

That result was an important reminder of the difference between identifying potentially interesting biological effects and demonstrating that those effects translate into meaningful improvements for patients.

Research has nevertheless continued.

A study published in September involving electronic health records from more than 63,000 semaglutide users with existing neurological or psychiatric conditions found that treatment was associated with lower rates of several subsequent neuropsychiatric diagnoses compared with some other diabetes medicines.

Researchers also found that higher semaglutide doses were associated with lower subsequent incidence of several categories of conditions, including mood, anxiety and substance-related disorders.

Those results should be interpreted particularly carefully. The research was observational, meaning it can identify associations but cannot establish that semaglutide prevented those conditions. Differences between people prescribed different medicines, their underlying health and numerous other factors could influence the results.

What is becoming increasingly clear is that scientists’ understanding of GLP-1 medicines is evolving.

A recent Yale study has even challenged assumptions about how the drugs produce sustained weight loss.

Researchers had previously thought GLP-1 treatment worked partly by suppressing AgRP neurons, sometimes described as hunger neurons because of their role in stimulating eating.

Experiments in mice instead found that chronic GLP-1 treatment recruited those neurons as part of a metabolic response that helped sustain fat loss. When researchers genetically removed the AgRP neurons, the drugs could no longer maintain the same weight-loss effect.

The findings come from animal research and cannot automatically be translated to humans, but they demonstrate how much remains unknown about medicines already being taken by millions of people.

Ozempic was developed to treat type 2 diabetes, while Wegovy contains the same active ingredient at doses approved for chronic weight management. Their success has led to an extraordinary expansion of GLP-1 research into cardiovascular disease, kidney disease, sleep apnoea, liver disease and numerous other conditions.

The brain may prove to be another important part of that story.

Describing GLP-1 drugs as “rewiring” or “reshaping” the brain can sound alarming, but brains are not static structures. Neural activity and connections change continually in response to learning, behaviour, environment, medication and changes elsewhere in the body.

The important questions are therefore not simply whether GLP-1 medicines affect the brain, but precisely which pathways they influence, whether those changes persist after treatment stops and what they mean for people’s health and behaviour over many years.

Scientists do not yet have those answers.

What they are discovering is that the extraordinary effectiveness of medicines such as semaglutide may not be explained solely by slower digestion or a suppressed appetite. The drugs appear to interact with complex communication systems connecting the gut, metabolism and brain.

That could eventually help explain why some people taking them describe changes extending far beyond what is on their plate.

For now, those experiences are providing researchers with questions rather than definitive answers. With millions of people now using GLP-1 medicines worldwide, finding those answers has become increasingly important.

Stay informed with the stories shaping health and social care.

Register with The Daily Round for the latest sector news, inspections & reports, wellbeing content, workforce insights, expert features and practical updates—delivered free to your inbox.